Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 198 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menopausal Hot Flashes Clear all
Completed Phase 3 Interventional Results available

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

NCT01361308
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
74
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

NCT00003739
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional

Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.

NCT03564665
View directory record Official record
Conditions
Hot Flashes
Interventions
400mg Magnesium Glycinate BID, Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional Results available

Three Different Programs of Paced Breathing in Treating Hot Flashes in Women

NCT00569166
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hot Flashes, Sleep Disorders
Interventions
Paced breathing (15 min once daily, 6 breaths/min), Paced breathing (15 min twice daily, 6 breaths/min), Paced breathing (10 min once daily, 14 breaths/min)
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT05351892
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional Results available

A Mind-Body Intervention for Hot Flash Management

NCT03572153
View directory record Official record
Conditions
Hot Flashes, Postmenopausal Symptoms, Breast Cancer
Interventions
Self-Administered Hypnosis, Self-Administered White Noise Hypnosis
Behavioral
Lead sponsor
Baylor University
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

NCT00022074
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Hot Flashes
Interventions
gabapentin, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

NCT04600336
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
103
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 11, 2026, 9:49 PM EDT
Not yet recruiting Phase 3 Interventional

Fezolinetant and Vascular Health and Brain Health

NCT07606664
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
Placebo, Fezolinetant
Drug
Lead sponsor
Rebecca Thurston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

NCT00031720
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Hot Flushes
Interventions
soy protein, isoflavones, Tamoxifen, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
14
States / cities
Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors

NCT01005108
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer

NCT00060320
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
black cohosh, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Venlafaxine and Hypnosis or Focused Attention in Treating Patients with Hot Flashes

NCT01000623
View directory record Official record
Conditions
Hot Flashes
Interventions
venlafaxine, placebo, hypnotherapy, mind-body intervention procedure
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

NCT05042362
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition

NCT01141972
View directory record Official record
Conditions
Hot Flushes, Menopause, Premature, Obesity, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

NCT03034018
View directory record Official record
Conditions
Insomnia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 11, 2026, 9:49 PM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAMe for Hot Flashes

NCT01140646
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Hot Flashes
Interventions
S-adenosyl-L-methionine disulfate p-toluene-sulfonate, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

NCT00206622
View directory record Official record
Conditions
Hot Flashes
Interventions
Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2009 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Womens Study to Alleviate Vasomotor Symptoms

NCT04587154
View directory record Official record
Conditions
Hot Flashes
Interventions
low-fat vegan diet with 1/2 cup soybeans daily
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Not applicable Interventional

Cooling Vest in Men With Hot Flashes

NCT03000322
View directory record Official record
Conditions
Hot Flashes
Interventions
Cooling Vest
Device
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

NCT03640754
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
G-CSF, Placebo/Saline
Biological · Other
Lead sponsor
MenoGeniX, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 11, 2026, 9:49 PM EDT
Withdrawn Phase 2 Interventional

Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans

NCT05073237
View directory record Official record
Conditions
Menopause, Prediabetes, Obesity
Interventions
Placebo, conjugated estrogens/bazedoxifene (CE/BZA)
Other · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 11, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

NCT04003389
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
142
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 11, 2026, 9:49 PM EDT